Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Pract Radiat Oncol. 2020 Feb 13;10(6):e495–e507. doi: 10.1016/j.prro.2020.01.012

Figure 4.

Figure 4

Case 2: Patient selection for stereotactic body radiation therapy for locally advanced pancreatic cancer. A 3-cm pancreatic head mass encases the common hepatic and splenic artery and invades the portal and superior mesenteric veins. No regional adenopathy is appreciated. After neoadjuvant chemotherapy with excellent clinical response (decrease in size of the mass and vein involvement), there was continued involvement of the common hepatic artery and origin of the splenic artery. The patient was selected for a dose-escalation stereotactic body radiation therapy protocol after meeting inclusion criteria (Table 2). Treatment dose and fractionation selected was 5000 cGy in 5 fractions with prescription dose to be confined to the tumor with small margin as surgical considerations were a future possibility for this patient.